A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome
This report describes the case of a 67-year-old male with inflammatory breast cancer. He had noticed a left breast mass about seven years previously, but he had ignored it. He then visited our hospital 4 months previously when multiple small masses occurred in the left front chest wall. The tumor was diagnosed as skin metastasis of breast cancer by skin biopsy and he was referred to our department. The tumor cells were positive for estrogen receptor and progesterone receptor, and negative for HER2/neu, and the Ki67 expression was 10-15%. The subtype of his breast cancer was luminal A type. It had secondary inflammatory breast cancer and preceded chemotherapy. Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted. 3 courses of docetaxel every 3 weeks failed to control the disease. Since an obstruction of the right iliac artery was newly observed, the anticoagulant was changed to cilostazol and rivaroxaban, but left second finger and fourth finger necrosis occurred due to peripheral circulatory failure. The condition of the disease was stabilized by FEC (5-FU, epirubicin, cyclophosphamide) therapy, but it became difficult to secure the blood vessel. Without constructing a CV port because of the thrombus, chemotherapy was changed to S-1 oral administration, and strength to the chest wall Modulated radiotherapy intensity modulated radiation therapy (IMRT) was performed. Although the tumor was reduced, the condition of the whole body gradually weakened and the patient died a year and a half after the start of the treatment. This case of inflammatory luminal in male breast cancer that caused thrombus was difficult to treat. Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of UOEH - 41(2019), 2 vom: 03., Seite 211-216 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Tashima, Yuko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 24.12.2019 Date Revised 24.12.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7888/juoeh.41.211 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM299055574 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM299055574 | ||
| 003 | DE-627 | ||
| 005 | 20231225095514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.7888/juoeh.41.211 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0996.xml |
| 035 | |a (DE-627)NLM299055574 | ||
| 035 | |a (NLM)31292366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Tashima, Yuko |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.12.2019 | ||
| 500 | |a Date Revised 24.12.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This report describes the case of a 67-year-old male with inflammatory breast cancer. He had noticed a left breast mass about seven years previously, but he had ignored it. He then visited our hospital 4 months previously when multiple small masses occurred in the left front chest wall. The tumor was diagnosed as skin metastasis of breast cancer by skin biopsy and he was referred to our department. The tumor cells were positive for estrogen receptor and progesterone receptor, and negative for HER2/neu, and the Ki67 expression was 10-15%. The subtype of his breast cancer was luminal A type. It had secondary inflammatory breast cancer and preceded chemotherapy. Also, as the veins in the lower extremity were filled with thrombus, we gave him an anticoagulant (Edoxaban), but due to the malignant hyper coagulable state (Trousseau syndrome) a CV port could not be implanted. 3 courses of docetaxel every 3 weeks failed to control the disease. Since an obstruction of the right iliac artery was newly observed, the anticoagulant was changed to cilostazol and rivaroxaban, but left second finger and fourth finger necrosis occurred due to peripheral circulatory failure. The condition of the disease was stabilized by FEC (5-FU, epirubicin, cyclophosphamide) therapy, but it became difficult to secure the blood vessel. Without constructing a CV port because of the thrombus, chemotherapy was changed to S-1 oral administration, and strength to the chest wall Modulated radiotherapy intensity modulated radiation therapy (IMRT) was performed. Although the tumor was reduced, the condition of the whole body gradually weakened and the patient died a year and a half after the start of the treatment. This case of inflammatory luminal in male breast cancer that caused thrombus was difficult to treat. Thrombosis in advanced cancer patients is often pointed out, but since male breast cancer patients tend to take a long time to visit the hospital after becoming aware of the mass and arrive at an advanced state, it is necessary to notify the public of the existence of male breast cancer | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Trousseau syndrome | |
| 650 | 4 | |a inflammatory breast cancer | |
| 650 | 4 | |a male breast cancer | |
| 650 | 4 | |a thromboembolism | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Factor Xa Inhibitors |2 NLM | |
| 650 | 7 | |a Pyridines |2 NLM | |
| 650 | 7 | |a Thiazoles |2 NLM | |
| 650 | 7 | |a S 1 (combination) |2 NLM | |
| 650 | 7 | |a 150863-82-4 |2 NLM | |
| 650 | 7 | |a Tegafur |2 NLM | |
| 650 | 7 | |a 1548R74NSZ |2 NLM | |
| 650 | 7 | |a Docetaxel |2 NLM | |
| 650 | 7 | |a 15H5577CQD |2 NLM | |
| 650 | 7 | |a Epirubicin |2 NLM | |
| 650 | 7 | |a 3Z8479ZZ5X |2 NLM | |
| 650 | 7 | |a Oxonic Acid |2 NLM | |
| 650 | 7 | |a 5VT6420TIG |2 NLM | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Cilostazol |2 NLM | |
| 650 | 7 | |a N7Z035406B |2 NLM | |
| 650 | 7 | |a edoxaban |2 NLM | |
| 650 | 7 | |a NDU3J18APO |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Kusanagi, Kasumi |e verfasserin |4 aut | |
| 700 | 1 | |a Takeda, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshimatsu, Katsuma |e verfasserin |4 aut | |
| 700 | 1 | |a Ishida, Teruaki |e verfasserin |4 aut | |
| 700 | 1 | |a Shinohara, Shinji |e verfasserin |4 aut | |
| 700 | 1 | |a Hirai, Ayako |e verfasserin |4 aut | |
| 700 | 1 | |a Imanishi, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Ichiki, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Fumihiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of UOEH |d 1987 |g 41(2019), 2 vom: 03., Seite 211-216 |w (DE-627)NLM013057219 |x 0387-821X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2019 |g number:2 |g day:03 |g pages:211-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7888/juoeh.41.211 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2019 |e 2 |b 03 |h 211-216 | ||